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The Science for Life Laboratory Drug Discovery and Development (SciLifeLab DDD) platform reaches out
to Swedish academia with an industry-standard infrastructure for academic drug discovery, supported
by earmarked funds from the Swedish government. In this review, we describe the build-up and
operation of the platform, and reflect on our first two years of operation, with the ambition to share
learnings and best practice with academic drug discovery centers globally. We also discuss how the
Swedish Teacher Exemption Law, an internationally unique aspect of the innovation system, has shaped
the operation. Furthermore, we address how this investment in infrastructure and expertise can be
utilized to facilitate international collaboration between academia and industry in the best interest of
those ultimately benefiting the most from translational pharmaceutical research – the patients.Swedish pharmaceutical industry and research
Being a small country with only 10 million inhabitants, Sweden
has a proud history of successful organic growth of its pharmaceu-
tical industry with companies such as Kabi [the first company to
license Genentech’s recombinant DNA technology later overtaken
by Pharmacia (subsequently merging with Upjohn, and later being
closed as a part of Pfizer)], Ha¨ssle (bought by Astra) and Astra
(merged with Zeneca to form AstraZeneca). Even today, after the
closure of three out of four major global pharma research sites
located in Sweden, pharmaceuticals still represent one of Sweden’s
largest export products (a large part originating from AstraZenca’s
manufacturing plant in So¨derta¨lje). The aftermath of the indus-
try’s turbulent reorganization has created several geographical
areas with strong life science innovation capacity [i.e. Stock-
holm/Uppsala (51% of life science companies), Malmo¨/Lund
(19%) and Go¨teborg (17%)], hosting a plethora of smaller biotech
companies (the largest now being Medivir outside Stockholm) [1].Corresponding author: Arvidsson, P.I. (Per.Arvidsson@scilifelab.se)
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1359-6446/ 2016 The Authors. Published by Elsevier LtMany of the products that became the cornerstones of the
Swedish pharma and biotech industry (Macrodex1, Xylocain1,
Seloken1, Healon1, Pulmicort1, Genotropin1, Losec1, Olysio1,
among others) were based on discoveries made at, or in close
collaboration with, academia [2]. In today’s more fragmented
industrial landscape there is a need for a new framework to capi-
talize on existing innovative research at universities, and to lever-
age projects with a capacity for generating new drug candidates. In
the Research and Innovation Bill 2012, the Swedish Government
allocated approximately US$6 million per year (2013–2016) to
establish a drug discovery effort at the national Science for Life
Laboratory (SciLifeLab) as one effort toward this goal. The aim was
to build on Sweden’s long tradition in drug development, and to
expose academic drug discovery projects to opportunities for in-
ternational collaborations, grants and investments.
SciLifeLab
SciLifeLab is a Swedish center for molecular biosciences with
focus on health and environmental research [3–5]. The center
combines frontline technical expertise with advanced knowledged. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
http://dx.doi.org/10.1016/j.drudis.2016.06.026
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ADME relates to a drugs – adsorption, distribution,
metabolism and excretion.
CD candidate drug – the final product of the preclinical
development of a pharmacological substance that has
undergone regulatory safety studies that allows first-time-in-
human dosing.
Hit2Lead the process of going from an initial validated
chemical starting point ‘hit’, typically identified from a high-
throughput screen, to a molecule with partially optimized
properties for in vivo use (e.g. potency, solubility, metabolic
stability, permeability, etc.).
SAR relates to how structural changes among a series of
small molecule compounds effect potency, ADME and other
properties of importance for a safe drug.
Screening cascade the iterative process by which a small
molecule or biological therapeutic that meets the TPP will be
optimized and identified.
TPP target product profile document tries to outline the
desired properties of the proposed new drug already at the
start of the project; two important questions to answer early
on is how the proposed product will differentiate from
current therapies and medical practice in a value-adding way
and how preclinical results will be translated to a clinically
measurable response.
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with two nodes, one in Uppsala and one in Stockholm, is a
national resource hosted by four universities together: Karolinska
Institutet, KTH Royal Institute of Technology, Stockholm Univer-
sity and Uppsala University. Researchers from all of Sweden can
use the technology and the knowhow available at SciLifeLab. In
addition, SciLifeLab aims to create a strong research community
through workshops, seminars and courses. Users of technologies
and expertise provided by SciLifeLab are found within academia,
industry, authorities and healthcare. SciLifeLab also encourages
partnerships and mediates collaborations between players in the
life science sector.
SciLifeLab DDD platform and the objective of this
article
SciLifeLab Drug Discovery and Development (SciLifeLab DDD) has
been set up as a platform for early drug discovery and development
and commenced its operation in early 2014. In this paper we
discuss the platform as one of several possible ways to stimulate
translational research. The SciLifeLab DDD mission is to help
transfer basic research to early drug development programs, and
to build an environment for scientific collaborations of interna-
tional standard, competence and advanced infrastructure in the
area of drug discovery. The platform offers intellectual and tech-
nical assistance to individual research groups with pharmaceutical
projects. In addition, we strive to establish SciLifeLab DDD as a
natural portal and collection point for Swedish academic drug
discovery efforts. A further aim is to establish an attractive envi-
ronment for collaboration between academia and industry in the
context of SciLifeLab’s overall mission. Herein, we present the
infrastructure from an international perspective, and discuss how
this national resource could help engage academic researchersmore widely in private and public international initiatives aiming
to bring new medicines to patients. We also reflect on lessons
learned from our two first years of operation, with the hope that
this will be useful to other new academic drug discovery centers
being set up globally.
A changing role of academia in drug discovery and
different ‘business models’ for academic drug discovery
centers
The global pharmaceutical industry is currently undergoing a
paradigm shift where more early drug research is done in collabo-
ration with academia and through public–private partnerships [6].
The role of academia in the development of new drugs has been
summarized [7–9], and these studies show that the most innova-
tive drugs during the period 1998–2007 originated in academia
and small biotech companies and not in the large pharmaceutical
companies. Kneller’s analysis [9] also showed a project flow from
academia through small companies to large pharmaceutical com-
panies for registration, approval and marketing. This clearly
demonstrates the need for all these actors in the value-chain of
drug discovery and development, and emphasizes academia as a
vital initiator of successful drug discovery.
Many universities in the USA [10] and in Europe [11] have
created units for academic drug discovery to take an active role
in this changing landscape for pharmaceutical research. These new
centers are important for coordination of activities, and are aimed
at meeting the demand of a more active academia in bringing drug
discovery projects toward the clinic. Several of these can be found
through the organization AD2C (Academic Drug Discovery Con-
sortium; http://www.addconsortium.org) [12]. For the purpose of
comparison in this article, we selected a few international centers
and grouped them into three broad categories (Table 1).
Investment-funded centers
Medical Research Council Technologies (MRCT), UK, Cancer Re-
search Technology (CRT), UK, and Center for Drug Design and
Discovery (CD3), Belgium, are examples of technology-transfer
organizations from not-for-profit organizations with a clear aim to
generate a return on investment for their organizations by licenses
and royalties. MRCT and CRT have the rights to commercialize all
projects supported by the Medical Research Council and the UK
Cancer Research foundation, respectively. MRCT and CD3 origi-
nally focused on commercialization of internal research and tech-
nologies but now also make venture capital investments and seek
external global opportunities for co-development. The strength of
these centers is that they are self-sustained with strong funding
from previous exits. They are role-models for commercialization of
academic research with industry-standard business development
function and resources and scope that are much larger than most
academic drug discovery centers.
Alliance-funded centers
Max Planck Lead Discovery Center (LGC), Germany, Vanderbilt
Center for Neuroscience Drug Discovery (VCNDD), USA, and
RIKEN, Japan, are prominent examples of academic drug discovery
centers with a clear mission to set up and commercialize drug
discovery programs originating from within the Max Planck soci-
ety, Vanderbilt and RIKEN, respectively. These centers typicallywww.drugdiscoverytoday.com 1691
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TABLE 1
Categorization of international academic drug discovery centers
Center type Example Strengths Budget/FTEs
Investment-funded centers MRCT (UK), CRT (UK), CD3 (Belgium) Strong funding, self sustainable,
industry-standard business development
MRCT: 130 FTEs
CRT: £350 million per year
CD3: s24 million fund
Alliance-funded centers LGC (Germany), VCNDD (USA),
RIKEN DD (Japan)
Industry funding of program,
commercial interest secured
Project-specific – industrial rate
Research-funded centers Broad (USA), DDU (UK), EIDD (USA) Science driven, follow academic funding Project-specific – depends on grants
Abbreviations: CD3, Center for Drug Design and Discovery; CRT, Cancer Research Technology; DDU, Drug Discovery Unit University of Dundee; EIDD, Emory Institute for Drug Development;
LGC, Max Planck Lead Discovery Center; MRCT, Medical Research Council Technologies; VCNDD, Vanderbilt Center for Neuroscience Drug Discovery.
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vidual program, and that organization then funds the further
development of the program (up to clinical trials or beyond)
within the academic organization. The strength of this model is
that it opens a new funding stream and assures a commercial
interest of the final product early on.
Research-funded centers
Broad Center for the Development of Therapeutics, USA, the Drug
Discovery Unit at the University of Dundee (DDU), UK, and Emory
Institute for Drug Development (EIDD), USA, are examples of
centers that combine a core funding with research funding for
an individual program from more-traditional academic funding
organizations (e.g. Wellcome trust and Bill & Melinda Gates
Foundation). Often, these actors have a strong support network
to work on a dedicated disease focus (i.e. tropical diseases at DDU
and viral disease at EIDD). The strength of this approach is that it is
driven primarily by scientific excellence and reflects the academic
funding to an individual principal investigator (PI) or disease area.
Although some organizations are well funded from a combina-
tion of core funding, grants and alliances, it is still reasonable to
ask why these relatively modest investments in academic drug
discovery would be successful when the global pharmaceutical
industry, despite billions of dollars of investments, fails to deliver
new products at a pace that satisfies unmet medical needs and
shareholders’ expectations [6,13,14]. We believe that the key for
success is to identify, and interact closely with, researchers con-
ducting cutting-edge biological research, where academic and
industrial drug discovery programs are built but lack the knowl-
edge or resources to bring discoveries to the patients. In addition,
rather than taking over the researchers’ project, we believe that
working together with scientists to translate their discoveries
toward true patient benefit would be more efficient and rewarding
for both parties. Academic scientists in general are not trained in
drug discovery and an independent group of professional drug
hunters could help to clarify important factors for progression of
projects into clinical studies and add the needed technical drug
discovery knowhow into the existing academic community.
Considerations for establishing an academic drug
discovery platform in Sweden
The Teacher Exemption Law, unique to Sweden, influenced our
planning and ways of working at SciLifeLab DDD. This law states
that the individual scientist, not the university, owns their dis-
coveries and it allows them to commercialize discoveries made1692 www.drugdiscoverytoday.comfrom publicly funded research and thereby be personally account-
able for any financial risk and reward during this process. The main
objective of SciLifeLab DDD is to be a facilitator for Swedish
academic researchers to bring their basic biological discoveries
toward patient benefit. The ultimate goal is to provide more
clinical candidates for further studies in humans, but realistically
such a goal is associated with a very high risk in the long-term,
because it requires investment of hundreds of millions of dollars
and 6–7 years of development. Both these aspects made us decide
to focus our assistance early in the value chain of a drug project.
Later parts, which require greater capital and longer time-lines, are
better done with a shared risk or reward from private and public
funds. Moreover, SciLifeLab DDD is an academic activity hosted by
four universities. As such, the guiding principle should be based on
academia’s missions: research, education and interaction with the
surrounding society (in particular industry and healthcare). When
a drug discovery project becomes commercially viable, it needs to
seek funding from other sources than those financing basic re-
search.
By acting in the early phase of drug discovery, SciLifeLab DDD
also avoids competition with companies specializing in contract
research services. Instead, it is anticipated that, by emphasizing
the quality of data required for a drug discovery project to attract
seed investments for continued development, the service and
competence that are offered through consultants and contract
laboratories become more visible to the start-up and academic
community. Thus, it is anticipated that a virtual company model,
similar to the alliance-funded centers concept, could emerge after
the involvement of SciLifeLab DDD. In addition, there are other
tools in place in the Swedish innovation system for later phase
projects sponsored by Vinnova – the Swedish innovation agency.
How to secure commercial interest at the receiving end
At the front end of the drug discovery value chain is basic academic
research that emerges from the large-scale platforms within the
national SciLifeLab, for example the National Genomics Infra-
structure [15] and the Chemical Biology Consortium Sweden
[16]. These contributors strengthen target identification and vali-
dation through genomic sequencing and screening for tool com-
pounds, respectively. The focus of SciLifeLab DDD will therefore be
to assist projects that have a defined rationale for a drug discovery
program up to a point where the project has matured enough to be
of interest for commercial partners or granting agencies specializ-
ing in commercialization of projects. Our place in the value chain
should be viewed such that the final product from SciLifeLab DDD
Drug Discovery Today  Volume 21, Number 10 October 2016 REVIEWS
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preclinical efficacy in an appropriate model(s) with translational
values that support further development to clinical proof-of-con-
cept studies.
However, animal data alone is rarely enough to attract a poten-
tial commercial partner [17]. Many academic publications already
contain data from animal studies; but all too often such studies
have been done with known compounds and lack information on
fundamental compound properties such as solubility, permeabili-
ty, metabolism, dose–response, exposure, among others. More-
over, even basic views on how to bridge the laboratory-controlled
conditions in which the compound is active in animal models to
the complex situation in addressing human disease might be
lacking. To be of interest to commercial partners it is important
to have a clear understanding of future medical needs, a reasonable
rationale arguing for why the particular drug should be efficacious
in a specific category of patients, an analysis of the competitive
situation and not least an appreciation of which skills and strate-
gies are needed later in the development phase. To be successful,
early academic drug discovery projects also benefit from a clear
strategy for further preclinical and clinical development [i.e. a
target product profile (TPP) including a draft translational science
plan (Fig. 1)].
Organization of SciLifeLab DDD
At the outset, we decided that SciLifeLab DDD should be set up to
support small molecule and protein therapeutics drug discovery
programs. The rationale for including both being that the Chemi-
cal Biology Consortium Sweden, offering services for explorative
high-throughput screening to find chemical tools [16], was already
in place, as well as the collected knowhow around antibody
development originating from the Human Protein Atlas [18].
Given that SciLifeLab DDD should be open to accept project
proposals from all disease areas, we needed to build a genericTherap euti cs
Small molecules &
biologics
SciLifeLab DDD
Swedish  teach ers  exemption law 
individual researcher all IP 
Target
identification
-OMICS &
Chemical Biology
Q
Increasing knowledge  
FIGURE 1
The role of SciLifeLab Drug Discovery and Development (SciLifeLab DDD) platform 
enough to seek external funding or commercial partnerships. This is accomplishe
expertise in drug discovery and development. According to the Swedish Teacher Ex
research – no intellectual property (IP) ownership is therefore assigned to SciLifeinternal drug discovery engine, and rely on the project owner
for in-depth understanding of the biology and expertise in related
in vivo models. The platform thus has nine units, termed facilities
(Fig. 2). These are stationed at the SciLifeLab premises in Stock-
holm and Uppsala (from February 2016, the human antibody
therapeutics facility expanded its operation to Lund University)
but interact with researchers throughout the country for the
projects.
The compound handling and IT infrastructure facility works
together with the Chemical Biology Consortium Sweden [16] and
has access to approximately 200,000 chemical substances. The
unit offers substance handling and sends assay-ready plates across
the country. The group is also working to establish a national IT
infrastructure to store information about the biological properties
of the compounds that would allow easy access for the project
owner. The protein expression and characterization facility pro-
vides recombinant proteins from bacterial, insect and human cells
for drug discovery projects. The facility for biochemical and cellu-
lar screening has industry-standard robotics for conducting phar-
macological assays of compounds and proteins in plate formats.
Medicinal chemistry Hit2Lead (see Glossary) and lead ID offer
expertise in medicinal and computational chemistry for synthesis
of new drug candidates, and the biophysical screening and char-
acterization facility uses biophysical methods like surface plasmon
resonance (SPR) biosensor technology and structural biology to
characterize the binding of ligand and target protein. The ADME
group is part of Uppsala University Drug Optimization and Phar-
maceutical Profiling Platform (UDOPP) [19] and investigates in
vitro pharmacokinetic properties of drug candidates, in vivo expo-
sure and assists with early metabolic profiling. The in vitro and
systems pharmacology facility makes detailed mechanistic studies
of a substance mechanism of action and has access to patient-
derived cells for profiling. The human antibody therapeutics facil-
ity offers selection, characterization and development of human grants  the
rights!
External funding
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Clini cal
candidate
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is to translate basic biomedical research to a point where projects are mature
d by offering granted projects access to technical service and intellectual
emption Law, researchers have the right to commercialize the results of their
Lab DDD.
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FIGURE 2
SciLifeLab Drug Discovery and Development (SciLifeLab DDD) is organized in nine facilities and one management team. The nine facilities offer industry-standard
infrastructure and expertise for academic drug discovery projects. The management team offers strategic advice and support to scientists and innovation offices
in preparing target product profiles and plans for drug discovery projects.
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FIGURE 3
The assessment of an academic project’s potential as a drug discovery project
needs to include other factors than those traditionally used for evaluating
proposals submitted to funding agencies. Shown is the set of criteria
currently used by the platform steering group for project prioritization.
Competitive edge (differentiation) is the largest hurdle and needs to be
objectively assessed using professional competitive intelligence databases
and a continuous industry dialogue.
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braries. A total of 36 fully dedicated full-time employees (FTEs) at
the facilities are currently engaged in the work at the platform.
An international comparison, through a search in the AD2C
database, reveals that globally only a few centers offer a combina-
tion of small molecule and antibody based drug discovery capa-
bility. Likewise, ADME and systems pharmacology are capabilities
that are less common to the majority of academic drug discovery
centers. Starting in 2016, we also include drug safety assessment
capabilities within the platform; thereby, we will be able to make
an early assessment of the potential liabilities associated with
manipulation of the biological target of interest.
The facilities are each led by a head of facility. The platform as a
whole has two full-time directors leading the work in Stockholm
and Uppsala, respectively, and one project coordinator and,
through a strategic collaboration with the national center for
toxicological sciences SweTox, a drug discovery toxicologist.
The management team leads the overall activities of the platform.
This team also offers strategic advice and support to scientists and
innovation offices in preparing target product profiles and plans
for drug discovery projects. All the staff at the facilities work full-
time with the drug discovery projects within the platform. Twelve
professors at the host universities support projects with their
experience and assure that the facilities maintain the highest
scientific quality (e.g. with regard to technology development
they conduct their research separately from the facilities). The
directors, heads of facility and the professors make up the platform
leadership team, and report to an external platform steering group,
responsible for overall strategy and, most importantly, project
prioritization.
Collectively, the SciLifeLab DDD staff have more than 250 years
of industrial experience in drug development gathered from more
than 15 different pharmaceutical companies. Furthermore, the
staff and associated professors have experience from starting some
20 new companies; thus being able to offer valuable advice for
those researchers who wish to develop their drug projects further
through a separate company; with the Swedish Teacher Exemp-
tion Law, initiation of a start-up company to hold IP rights is often
required, even for projects seeking early licensing to a larger
company.1694 www.drugdiscoverytoday.comProject model
SciLifeLab DDD is a resource for all academic researchers with an
ambition to participate in drug development of small molecule
and protein therapeutics. This means that the platform has to
accommodate proposals from all kinds of disease areas and that
the specific biological knowledge and disease models need to be
available from the academic researcher or through their collabora-
tors. This generality is different from some of the international
centers listed above, which focus on particular therapeutic areas.
To secure transparency and thorough evaluation, an external
platform steering group composed of experts within clinical
medicine, financing and pharmaceutical industry prioritizes be-
tween the projects. A successful project needs to offer solutions for
a medical need, have a good rationale for the therapeutic mecha-
nism of action, present an advantage over any identified compe-
titors and be positively evaluated on several other parameters
(Fig. 3). The project must also be feasible within the financial
Drug Discovery Today  Volume 21, Number 10 October 2016 REVIEWS
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funding it hopes to attract to pursue the project further. Research-
ers apply for entry to the platform and, following a favorable
evaluation, SciLifeLab DDD provides the granted projects full
access to the infrastructure in the form of instrumentation, facili-
ties and personnel and the fee for the researcher is limited to the
cost of consumables.
During the course of a project, members from SciLifeLab DDD
and the research group jointly work on drug project, which
becomes a highly interdisciplinary endeavor. The core of the drug
discovery project at this stage is centered on the screening cascade
in the TPP (Fig. 4a). The screening cascade is the roadmap that,
already at the start of the project, outlines how an active small
molecule or antibody therapeutic with the requirements in the
TPP will be identified. All activities needed at the various facilities
are coordinated by the assigned SciLifeLab DDD project leader
according to a detailed Gantt chart (Fig. 4b) that spans a six-month
period. The steering board assigns priority to individual projects
and activities for 6 months, after which the project is subjected to
new evaluation in competition with new project proposals. Thus,
it is essential to define clear short-term stop–go decisions and
deliverables for a particular 6-month period so that each cycle
adds value to the project and allows the project to be progressed in
the PI group if priority would decrease for the next cycle.Library design
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FIGURE 4
(a) Example of a representative screening cascade for a small molecule oncology p
molecule or biological therapeutic that meets the target product profile (TPP). (b) R
work ongoing at the facilities for a small molecule drug discovery project in the e
competences, that is, PEC, protein expression and characterization; BCS, biochemic
ADME and Toxicology; BSC, biophysical screening and characterization; IVSP, in vitro
principal investigators own laboratory (not accounted in the Gantt).During the manning of the infrastructure we strived to recruit
individuals with experience from industrial drug development.
The research group is responsible for continued evolution of the
biology and for liaising with innovation offices, and future exter-
nal parties; however, we noted a large demand for assistance with
external interactions from our collaborating researchers, which
will demand a slight modification of our model (vide infra). Origi-
nally, we planned to support three full-size small molecule and
three biopharmaceutical projects running in parallel, but a high
demand on our services, and more-efficient use of available
resources, allowed us to increase the number of supported drug
discovery programs to 10–12 projects run in parallel. To fully
optimize the capacity of the platform and balance workload,
smaller service projects (i.e. requesting limited support from only
one facility) can be supported provided that they do not interfere
with prioritized programs.
Identifying academic research with potential for drug
development
Researchers interested in the service of SciLifeLab DDD are invited
to make contact for a first unconditional consultation. Such meet-
ings can be initiated by the individual researcher but we also spend
considerable time and effort to make ourselves known to Swedish
academics by hosting events and personal meetings at various4,3 4,3 3,5 5,7 5,7
Oct-15 Nov-15 Dec-15 Apr-16
Drug Discovery Today 
roject. The screening cascade is the roadmap to optimize and identify a small
epresentative Gantt chart demonstrating the highly cross-functional project
arly stage of Hit2Lead generation. See text for explanation of facility (team)
al and cellular screening; MedChem, medicinal chemistry Hit2Lead, ADMEoT
 and systems pharmacology; Cmd, C compound center; PI, resources from the
www.drugdiscoverytoday.com 1695
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ings and by working with the members of the innovation system
and funding agencies. The universities’ innovation offices have
proven to be a good channel to identify researchers with promising
projects. The innovation officers at the different universities often
have a good overview of which projects at their university are in
line with our mission. SciLifeLab DDD has the expertise and
experimental resources that are often needed to identify and fill
the gaps in promising early drug discovery projects identified by
the innovation offices. Innovation offices have access to comple-
mentary resources (e.g. patent attorneys and business develop-
ment capabilities that are essential for drug discovery projects).
Close collaboration with the universities’ innovation offices is
therefore instrumental for the SciLifeLab DDD operation.
SciLifeLab DDD aims to offer the researchers a useful, confiden-
tial opinion of their project’s advantages and disadvantages from a
drug discovery perspective. This feedback should also prove valu-
able to project proposals that are not prioritized by the platform
steering group. Indeed, many researchers testify that a first infor-
mal meeting with SciLifeLab DDD has led to improvement of their
regular funding applications. DDD assures that all shared infor-
mation is treated as confidential. If a project is considered to be
competitive, SciLifeLab DDD assigns one of the DDD directors as a
pre-project leader for the project to work together with the re-
search group to put together a full project proposal for further
assessment by the steering group. Some limited wet-lab activities
might take place during the pre-project phase (e.g. druggability
assessment and in vitro ADME profiling of tool compounds).
Owing to the highly cross-functional nature of drug discovery,
multiple interactions between the research group and SciLifeLab
DDD are needed to prepare the project before prioritization to
clarify project goals and to make plans. Researchers testify that
these TPPs and accompanying plans are of great value, even if the
steering group does not prioritize the project. We have changed
our operating model somewhat during the second year, and now
offer our support to bring forward TPPs for projects seeking alter-
native funding or ways to progress their drug discovery program,
and these plans are viewed as distinct deliverables from the DDD
platform.
Leveraging a national platform with international
collaboration and innovation
How can the Swedish Government’s investment in a national
infrastructure with industry-standard equipment and expertise
best serve its purpose? We believe that, on top of the projects
we have capacity to handle internally, we need to offer additional
value to the academic drug discovery community (e.g. by facili-
tating international efforts).
International public–private collaborations
One opportunity to add additional value beyond the internal
project work is to utilize the infrastructure investment to help
Swedish researchers participate in international collaborations,
such as the EU’s Horizon 2020 and the Innovative Medicines
Initiative (IMI). This is exemplified by the in vitro ADME profiling
facility at SciLifeLab DDD participating in the IMI program
ENABLE, which aims to develop new antibacterial agents [20],
and the Human Antibody Therapeutics Facility taking part in the1696 www.drugdiscoverytoday.comnew IMI program ULTRA-DD coordinated by Novartis and The
Structural Genomics Consortium [21]. In these cases, the instru-
mental throughput is not yet limiting (although it will be eventu-
ally), meaning that such collaborative projects can be harbored,
provided external funds are available to cover additional person-
nel, rent, among others. SciLifeLab DDD could be effectively
utilized for coordination of new international multicenter projects
(e.g. IT and substance management).
Academic interactions with open innovation initiatives
In addition to taking part in international public–private colla-
borations, SciLifeLab DDD should strive to represent a link be-
tween Swedish academic research in the drug discovery area and
the global pharmaceutical industry. Most large global pharmaceu-
tical companies offer an open innovation model for collaborative
early drug discovery projects. This should provide an opportunity
to establish fruitful exchange and collaborations with the global
pharmaceutical industry that covers all of Swedish academia.
Given the Swedish Teacher Exemption Law, many academics in
Sweden might prefer to apply to an organization that does not
place any restriction on future license or ownership, because the
open innovation calls offered by the pharmaceutical industry
usually entail some IP restrictions. Other scientists might prefer
to interact directly with a pharmaceutical company. We see an
opportunity for project proposals that have been prepared with the
input from industry-trained professionals at SciLifeLab DDD to be
more competitive in the global industrial open innovation system.
These projects have been pre-screened at a national level, the
researchers have been prepared for the demands put forward on
a project by industry and they will better understand the financial
value and risk of a project after being evaluated at SciLifeLab DDD.
Clearly, this represents a value that should be a win–win opportu-
nity for further interactions between the individual researcher,
SciLifeLab DDD, and the global industrial open innovation sys-
tem.
Reflections from 2 years of operation
Reflecting on our first 2 years of operation, we believe that we have
shared, and attempted to mitigate, many of the obstacles and
recommendations put forward in the excellent paper by Dahlin
et al. [22]. Below, we summarize our own experiences.
Need for dialogue and knowledge transfer
Maybe not unexpectedly, we have experienced something of a
‘cultural clash’ between purely academic investigator-initiated
research, where the main deliverable is publications in high-im-
pact journals, and, by contrast, the specific requirements for drug
discovery. The foundation for academic drug discovery is based on
scientific discoveries that in most cases have not been initiated
with drug discovery as a downstream aim. However, once the
decision is made to bring forward a compound and a translational
package of validated data supporting the target hypothesis, one
enters a stage where experiments are planned to reach specific
conclusions and to meet precise milestones. To use limited
resources efficiently, the SciLifeLab DDD platform needs to chal-
lenge projects and define clear stop–go criteria for further engage-
ment. These strict requirements can sometimes be difficult to
accept for academic researchers who are exposed to the industrial
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conducting research and development, we believe that undergrad-
uate and graduate training should include innovation and drug
discovery whenever appropriate. A graduate school in drug dis-
covery is already in place [23], and exchange between companies
and universities in the form of shared PhD students or postdocs
should be further encouraged.
Proposals to SciLifeLab DDD span project ideas emerging from
early basic research to projects almost ready to enter clinical
studies. Irrespective of background, our experience is that several
project proposals are not considered appropriate for the platform
as a result of lack of industrial competitiveness. Most principal
investigators we meet are internationally renowned and well
funded by national and international funding agencies. They
are aware of all the important academic competition, but less
often they follow the work that has been conducted in industry
(i.e. data reported in the patent literature or through other chan-
nels of information). On multiple occasions we have been able to
identify that there are several compounds marketed, or in late-
stage clinical trials, for the same target or mechanism as the
researchers describe as novel. To assure a holistic view of the target
and the disease landscape as a whole an unbiased literature search
in commercial databases such as Thomson Integrity1, Citeline1 or
similar is required. We thus conclude that the academic medical
research community that aims to search for new therapies would
benefit from a broader knowledge base when designing new
projects.
Understandably, there is also limited knowledge in the academ-
ic community about the extent of work, data and investments
required to bring new medicines to patients. These aspects need to
be considered from the very beginning when new active com-
pounds or biologics are identified in assays by screening or selec-
tion. Ultimately, a potential new candidate drug’s differentiation
versus current treatments and compounds should be demonstrat-
ed against major competitor compounds and drugs on the market.
Data supporting differentiation of the final product and feasibility
to conduct conclusive clinical studies are essential to justify and
attract the billions of dollars of investments that are required to
bring the project to the market and clinical practice.
In addition to the intellectual and practical services above, we
strive to establish SciLifeLab DDD as the natural portal for Swedish
academic drug discovery efforts. This means reaching out to the
broader community of life science actors (e.g. innovation offices,
translational and clinical research centers, funding agencies, in-
dustry, consultants, students, politicians, among others). To unite
and cover the interest of so many stakeholders, we recently started
a newsletter [24]. We also organize two mini-symposiums related
to DDD every year. We find that coaching, during individual
meetings and through workshops and conferences, is required
to raise awareness around these subjects to make academic drug
discovery more successful.
Technical assessment of project quality
An important task for the SciLifeLab DDD platform is to make
a fair assessment of the quality of the project based on the available
data generated from the principal investigator’s own laboratory
(i.e. the transfer of experimental data from a research laboratory to
the platform). The high degree of irreproducibility of complexbiological systems that has been the focus of intense debate
recently [25–27] makes this a challenge. In addition, there is a
risk that projects are based on results that originate from assay
artifacts caused by chemical pan-assay interference compounds
(PAINS) [28] in commercial chemical libraries or through a non-
validated and quality controlled assay. We have therefore estab-
lished an initial project period in which we establish crucial assays
in the proposed screening cascade at the SciLifeLab DDD platform
to avoid, to the best of our ability, these pitfalls. It has also proven
vital to have in-house access to the primary SAR driving assays
because the academic research group, owing to other engage-
ments, projects and limited resources, cannot always prioritize
these collaborative efforts.
One probable factor contributing to the limited reproducibility
of preclinical in vivo studies is the lack of exposure analysis. Many
published animal studies report effect as a function of dose,
without documented knowledge of plasma exposure in vivo. By
offering access to bioanalysis of small and large molecules through
our ADME facility we hope to increase the quality of the drug
discovery projects. We suggest that reproducibility of biological
studies could be improved if editors of leading journals encourage
that the actual concentration of the substance in plasma is
reported for in vivo results.
Strategies for further development and the Swedish Teacher
Exemption Law
The Swedish Teacher Exemption Law adds a dimension of com-
plexity to the way projects proceed after exiting the SciLifeLab
DDD platform. As personally being the owner of all IP and data
generated throughout the research project, an academic scientist
in Sweden is in a unique position to decide on how to proceed with
the project (e.g. apply for continued public funding, apply for
private funding within open innovation, license the program to an
industrial partner or form a start-up company). These different
paths require vastly different investment in terms of time, engage-
ment, funding and IP strategy, to name but a few variables. We
experience that researchers, often finding themselves in this posi-
tion for the first time, are perplexed by the multitude of options,
which calls for an independent speaking partner for these consid-
erations. Specialized structures at the Swedish universities, such as
innovation offices and holding companies should ideally be best
suited to handle such dialogues with an individual and give advice
on how a project should proceed. In a workshop held together
with these organizations in Sweden last year the specific chal-
lenges associated with the exit phase of a particular academic drug
discovery project were addressed.
SciLifeLab DDD strives to facilitate this transition by frontload-
ing the exit phase with close interactions with the university
innovation systems and by incorporating the researcher’s pre-
ferred exit strategy in the plans so that compounds with the right
characteristics are identified as early as possible. Nevertheless, we
foresee a potential liability that academic drug discovery projects
might not reach further development because of difficulties in
mobilizing the right expertise and resources to assure a commer-
cially viable continuation of the project. The Swedish Teacher
Exemption Law stimulates the entrepreneurship among scientists
at universities to bring their basic scientific discoveries toward
commercialization, and contributes to the Swedish innovationwww.drugdiscoverytoday.com 1697
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reduces the mandate of universities to make the best deal possible
for the results generated within a project. In this context, it is
important to remember that the scientist, being owner of their
invention, could have special preferences for how to progress their
project. Through active collaborative work, we believe that SciLi-
feLab DDD can take an important role in driving a constructive and
pragmatic dialogue between the research scientist and the univer-
sity innovation systems to find solutions for how to deliver com-
mercially attractive drug projects for further progress into the
clinic.
Drug repurposing: a ‘free’ opportunity for the global
pharmaceutical industry
Despite the limited time-frame in which the SciLifeLab DDD
platform has operated, we can conclude that many academic
drug discovery projects identify new and unexpected biological
activity of known drugs (i.e. by screening commercial sets like the
Prestwick Chemical Library1 in ingenious cellular models of hu-
man disease). This observation should be an encouragement for
those pharmaceutical companies that have shared their collections
of (closed) clinical compounds with academic drug discovery
centers, because the originator might still uphold patent protection
for such compounds. Likewise, such drug repurposing should be
highly beneficial for the patients because of shorter development
cycles. However, there is a risk that the uncertainty associated with
the patents, or perhaps inexperience on use-patent filing, licensing
and prosecution from all those involved, would exclude
much promising biology to be developed into human therapies.1698 www.drugdiscoverytoday.comTypically, these results instead end up in publications without
patent protection, thereby prohibiting further development by
the discoverer of the new use or the original license holder. Sharing
best practice of successful repurposing experiences [including IP
rights (IPR) and licensing terms] will hopefully remove some
of the uncertainties associated with this promising approach in
the future [29].
Concluding remarks
The objective of this article is to highlight the DDD platform
within SciLifeLab as the Swedish center for academic drug discov-
ery. We have described our mission and objectives within Swe-
den’s rather unique academic innovation system, characterized by
the Teacher Exemption Law that gives Swedish academic research-
ers the right to personally commercialize their discoveries. We
have also aimed to share our experiences in the hope that other
emerging centers could benefit from our ongoing learning on how
to gain the maximum output from the means at hand. Most
importantly, we signal not only our role as the Swedish power-
house for academic drug discovery but also our long-term ambi-
tion to use resources and expertise in international collaborations
within public and private partnerships, recently exemplified
through the IMI programs ENABLE and ULTRA-DD. We believe
that an open climate that allows sharing of physical entities such
as compounds, data and other resources as well as experiences and
best practices, between academic and industrial partners, will be a
prerequisite to increase the efficiency by which society and indus-
try bring new treatment to patients who urgently need remedies
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